Characteristics
|
OS
|
PFS
|
---|
Univariate
|
Multivariate
|
Univariate
|
Multivariate
|
---|
HR (95% CI)
|
p-value
|
HR (95% CI)
|
p-value
|
HR (95% CI)
|
p-value
|
HR (95% CI)
|
p-value
|
---|
Age
|
0.97 (0.94–1.00)
|
0.08
|
0.97 (0.93–1.00)
|
0.08
|
0.96 (0.93–1.00)
|
0.03
|
0.97 (0.93–1.00)
|
0.07
|
BMI
|
0.99 (0.91–1.07)
|
0.74
| | |
1.05 (0.97–1.13)
|
0.22
| | |
ECOG PS (1 vs. 0)
|
1.56 (0.83–2.91)
|
0.17
| | |
1.39 (0.74–2.61)
|
0.30
| | |
Clinical T (T3–4 vs. T1–2)
|
1.06 (0.62–1.80)
|
0.84
| | |
0.93 (0.54–1.58)
|
0.78
| | |
Clinical N (N+ vs. N0)
|
1.16 (0.50–2.70)
|
0.72
| | |
1.79 (0.72–4.46)
|
0.21
| | |
cTNM stage (III vs. II)
|
0.89 (0.50–1.56)
|
0.67
| | |
0.68 (0.40–1.17)
|
0.16
| | |
Time from NCRT to surgery
|
1.01 (0.94–1.09)
|
0.72
| | |
0.98 (0.91–1.06)
|
0.59
| | |
Surgical margin (R1 vs. R0)
|
2.62 (1.41–4.85)
|
0.002
|
3.63 (1.59–8.28)
|
0.002
|
4.37 (2.46–7.77)
|
< 0.001
|
4.16 (2.11–8.19)
|
< 0.001
|
TRG (2/3 vs. 0/1)
|
3.42 (2.00–5.84)
|
< 0.001
|
2.84 (1.50–5.37)
|
0.001
|
2.39 (1.44–3.98)
|
0.001
|
2.31 (1.30–4.12)
|
0.004
|
Gross tumor volume
|
1.003 (1.000–1.005)
|
0.09
|
0.998 (0.994–1.002)
|
0.27
|
1.001 (0.998–1.004)
|
0.44
| | |
Target volume
|
1.00 (1.00–1.00)
|
0.12
| | |
1.00 (1.00–1.00)
|
0.63
| | |
Radiation dose
|
1.00 (1.00–1.00)
|
0.16
| | |
1.00 (1.00–1.00)
|
0.32
| | |
DVH of lunga
|
V5
|
1.02 (1.01–1.03)
|
0.001
|
1.02 (1.00–1.05)
|
0.03
|
1.01 (1.00–1.02)
|
0.03
|
1.01 (0.99–1.03)
|
0.21
|
V20
|
1.07 (1.04–1.11)
|
< 0.001
|
1.09 (1.04–1.14)
|
< 0.001
|
1.06 (1.02–1.10)
|
0.002
|
1.07 (1.03–1.12)
|
0.001
|
Mean heart dose
|
1.00 (1.00–1.01)
|
0.03
|
1.00 (1.00–1.00)
|
0.55
|
1.00 (1.00–1.00)
|
0.41
| | |
- Abbreviations: BMI body mass index, CI confidence interval, DVH dose-volume histogram, ECOG Eastern Cooperative Oncology Group, HR hazard ratio, NCRT neoadjuvant chemo-radiotherapy, TRG tumor regression grade, PS performance status
- Bolded p-values are those significant with a p < 0.05
- aVx = volume (mL) of lung receiving X Gy or more